RhumbLine Advisers’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-11,537
| Closed | -$33.8K | – | 4299 |
|
|
2024
Q2 | $33.8K | Sell |
11,537
-23,459
| -67% | -$68.7K | ﹤0.01% | 3780 |
|
|
2024
Q1 | $139K | Buy |
34,996
+1,201
| +4% | +$4.76K | ﹤0.01% | 3336 |
|
|
2023
Q4 | $168K | Buy |
33,795
+1,281
| +4% | +$6.37K | ﹤0.01% | 3268 |
|
|
2023
Q3 | $164K | Buy |
32,514
+1,510
| +5% | +$7.63K | ﹤0.01% | 3260 |
|
|
2023
Q2 | $156K | Buy |
+31,004
| New | +$156K | ﹤0.01% | 3362 |
|
|
2018
Q2 | – | Sell |
-878
| Closed | -$21K | – | 2924 |
|
|
2018
Q1 | $21K | Buy |
878
+31
| +4% | +$741 | ﹤0.01% | 2810 |
|
|
2017
Q4 | $159K | Sell |
847
-167
| -16% | -$31.3K | ﹤0.01% | 2691 |
|
|
2017
Q3 | $218K | Buy |
1,014
+16
| +2% | +$3.44K | ﹤0.01% | 2687 |
|
|
2017
Q2 | $205K | Buy |
998
+160
| +19% | +$32.9K | ﹤0.01% | 2748 |
|
|
2017
Q1 | $153K | Buy |
838
+38
| +5% | +$6.94K | ﹤0.01% | 2717 |
|
|
2016
Q4 | $200K | Buy |
800
+52
| +7% | +$13K | ﹤0.01% | 2673 |
|
|
2016
Q3 | $156K | Buy |
748
+85
| +13% | +$17.7K | ﹤0.01% | 2746 |
|
|
2016
Q2 | $134K | Buy |
+663
| New | +$134K | ﹤0.01% | 2863 |
|